Literature DB >> 15887248

Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase.

V Uma Bai1, Eugenia Cifuentes, Mani Menon, Evelyn R Barrack, G Prem-Veer Reddy.   

Abstract

We have shown previously that androgen receptor (AR) activity is required for the progression of cells from G(1) to S phase. In an attempt to elucidate the mechanism of androgen- and androgen-receptor-mediated proliferation of prostate cancer cells, we studied the effect of anti-androgen bicalutamide (Casodex) on the expression of cell-cycle regulatory genes in synchronized LNCaP cells progressing from G(1) to S phase. LNCaP cells were synchronized by isoleucine-deprivation. Expression of cell-cycle regulatory genes in S phase control cells versus Casodex-treated cells that fail to enter S phase was studied using a microarray containing cDNA probes for 111 cell-cycle specific genes. RT-PCR and Western-blots were used to validate microarray data. Casodex blocked synchronized LNCaP cells from entering S phase. Microarrays revealed downregulation of eight genes in cells prevented from entering into S phase by Casodex. Of these eight genes, only Cdc6, cyclin A, and cyclin B were downregulated at both the mRNA and protein level in Casodex treated cells as compared to control cells. The mRNA and protein levels of Cdc6 increased as synchronized LNCaP cells progressed from G(1) to S phase, and were attenuated in Casodex-treated cells failed to enter S phase. Cyclins A and B were detected when cells entered S phase, but not when they were in G(1) phase. Like Cdc6, the levels of both cyclins A and B were attenuated in Casodex-treated cells. AR may play an important role in the onset of DNA synthesis in prostate cancer cells by regulating the expression and stability of Cdc6, which is critically required for the assembly of the pre-replication complex(pre-RC). (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15887248     DOI: 10.1002/jcp.20422

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  22 in total

1.  Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.

Authors:  Shaoyong Chen; Sarah Gulla; Changmeng Cai; Steven P Balk
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

2.  RNA polymerase II transcription is required for human papillomavirus type 16 E7- and hydroxyurea-induced centriole overduplication.

Authors:  A Duensing; Y Liu; N Spardy; K Bartoli; M Tseng; J-A Kwon; X Teng; S Duensing
Journal:  Oncogene       Date:  2006-07-03       Impact factor: 9.867

3.  Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Lizamma Antony; Susan Dalrymple; Angelo M De Marzo; Charles G Drake; John T Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

4.  Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Authors:  John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

5.  MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor.

Authors:  Fajun Qu; Xingang Cui; Yi Hong; Junkai Wang; Yao Li; Lu Chen; Yushan Liu; Yi Gao; Danfeng Xu; Quanxing Wang
Journal:  Mol Cell Biochem       Date:  2013-02-17       Impact factor: 3.396

6.  Development of β-amino-carbonyl compounds as androgen receptor antagonists.

Authors:  Zhi-yun Zhang; Yan-hui Zhu; Cai-hong Zhou; Qing Liu; Hui-li Lu; Yun-jun Ge; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2014-05       Impact factor: 6.150

7.  Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Authors:  Styliani Karanika; Theodoros Karantanos; Likun Li; Jianxiang Wang; Sanghee Park; Guang Yang; Xuemei Zuo; Jian H Song; Sankar N Maity; Ganiraju C Manyam; Bradley Broom; Ana M Aparicio; Gary E Gallick; Patricia Troncoso; Paul G Corn; Nora Navone; Wei Zhang; Shuhua Li; Timothy C Thompson
Journal:  Cell Rep       Date:  2017-02-21       Impact factor: 9.423

8.  Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells.

Authors:  Arun Sivanandam; Shalini Murthy; Kannagi Chinnakannu; V Uma Bai; Sahn-Ho Kim; Evelyn R Barrack; Mani Menon; G Prem-Veer Reddy
Journal:  J Cell Physiol       Date:  2011-07       Impact factor: 6.384

9.  ATM Inhibition Potentiates Death of Androgen Receptor-inactivated Prostate Cancer Cells with Telomere Dysfunction.

Authors:  Vidyavathi Reddy; Min Wu; Nicholas Ciavattone; Nathan McKenty; Mani Menon; Evelyn R Barrack; G Prem-Veer Reddy; Sahn-Ho Kim
Journal:  J Biol Chem       Date:  2015-09-02       Impact factor: 5.157

10.  A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.

Authors:  Feng Jin; Joseph D Fondell
Journal:  Nucleic Acids Res       Date:  2009-06-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.